{
      "Rank": 476,
      "Acronym": [
            "CERES"
      ],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Three (3) subjects will be treated with a single administration of 2 x 10^7 (20 million) UCMSCs delivered via peripheral intravenous infusion.",
            "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
            "Three (3) subjects will be treated with a single IV administration of 2 x 10^7 (20 million) BMMSCs delivered via peripheral intravenous infusion.",
            "Three (3) subjects will be treated with a single IV administration of 1 x 10^8 (100 million) BMMSCs delivered via peripheral intravenous infusion.",
            "Participants randomized to receive a single administration of 1 x 10^8 (100 million) UCMSCs delivered via peripheral intravenous infusion.",
            "Participants randomized to receive a single administration of 1 x 10^8 (100 million) BMMSC delivered via peripheral intravenous infusion.",
            "Participants randomized to receive a single administration of placebo via peripheral intravenous infusion."
      ],
      "ArmGroupInterventionName": [
            "Biological: UCMSCs",
            "Biological: UCMSCs",
            "Biological: BMMSCs",
            "Biological: BMMSCs",
            "Biological: UCMSCs",
            "Biological: BMMSCs",
            "Other: Placebo"
      ],
      "ArmGroupLabel": [
            "Pilot Phase: Group 1 (UCMSCs - 20 million)",
            "Pilot Phase: Group 3 (UCMSCs - 100 million)",
            "Pilot Phase: Group 2 (BMMSCs - 20 million)",
            "Pilot Phase: Group 4 (BMMSCs -100 million)",
            "Group A (UCMSCs - 100 million)",
            "Group B (BMMSCs - 100 million)",
            "Group C (Placebo)"
      ],
      "ArmGroupType": [
            "Experimental",
            "Experimental",
            "Experimental",
            "Experimental",
            "Experimental",
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03059355"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study is to compare the safety and efficacy of UCMSCs and BMMSCs administered intravenously in patients to evaluate cytokine suppression in patients with chronic inflammation. Cells administered via intravenous infusion (IV) and will be tested in 37 patients in two phases (Pilot and Randomized)."
      ],
      "BriefTitle": [
            "Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression."
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "The Marcus Foundation"
      ],
      "CompletionDate": [
            "February 11, 2021"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Endothelial Dysfunction",
            "Metabolic Syndrome",
            "Chronic Inflammation"
      ],
      "ConditionAncestorId": [
            "D000004194",
            "D000010335",
            "D000007333",
            "D000006946",
            "D000044882",
            "D000008659"
      ],
      "ConditionAncestorTerm": [
            "Disease",
            "Pathologic Processes",
            "Insulin Resistance",
            "Hyperinsulinism",
            "Glucose Metabolism Disorders",
            "Metabolic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC18",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Nutritional and Metabolic Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Inflammation",
            "Metabolic Syndrome",
            "Syndrome"
      ],
      "ConditionBrowseLeafId": [
            "M9445",
            "M22158",
            "M15507",
            "M9522",
            "M9149",
            "M10791",
            "M24556",
            "T1303"
      ],
      "ConditionBrowseLeafName": [
            "Inflammation",
            "Metabolic Syndrome",
            "Syndrome",
            "Insulin Resistance",
            "Hyperinsulinism",
            "Metabolic Diseases",
            "Glucose Metabolism Disorders",
            "Chronic Graft Versus Host Disease"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000024821",
            "D000013577",
            "D000007249"
      ],
      "ConditionMeshTerm": [
            "Metabolic Syndrome",
            "Syndrome",
            "Inflammation"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [
            "Pilot phase is open-label. Randomized phase is blinded."
      ],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nProvide written informed consent\nSubjects age > 21 and < 95 years at the time of signing the Informed Consent Form.\nEach subject must have endothelial dysfunction.\n\nEndothelial dysfunction Criteria:\n\nImpaired flow-mediated vasodilation (FMD <7%)\n\n\u2022 At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following:\n\nWaist circumference - US defined: \u2265 102 cm (males) or \u2265 88 cm (females)\nElevated triglycerides - \u2265 150 mg/dL (1.7 mM)\nReduced HDL-C - Males: <40 mg/dL (1.0 mM) Females: <50 mg/dL (1.3 mM)\nElevated blood pressure - Systolic \u2265 130 mm Hg and/or Diastolic \u2265 85 mm Hg\nElevated fasting glucose - \u2265 100 mg/dL\n\nExclusion Criteria:\n\nBe a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.\nInability to perform any of the assessments required for endpoint analysis.\nActive listing (or expected future listing) for transplant of any organ.\nClinically important abnormal screening laboratory values, as determined by the P.I.\nSerious comorbid illness or any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.\nHave known allergies to penicillin or streptomycin.\nHypersensitivity to dimethyl sulfoxide (DMSO).\nBe a solid organ transplant recipient. This does not include prior cell-based therapy (>12 months prior enrollment) bone, skin, ligament, tendon or corneal grafting. Have a history of organ or cell transplant rejection.\nHave a clinical history of malignancy within 3 years (i.e., subjects with prior malignancy must be disease free for 3 years), except curatively- treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma, if recurrence occurs.\nHave a non-pulmonary condition that limits lifespan to < 1 year.\nHistory of drug abuse (illegal \"street\" drugs except marijuana, or prescription medications not being used appropriately for a pre-existing medical condition) or alcohol abuse (\u2265 5 drinks/day for \u02c3 3 months), or documented medical, occupational, or legal problems arising from the use of alcohol or drugs within the past 24 months.\nBe serum positive for HIV, hepatitis BsAg or Viremic hepatitis C, and/or Syphilis - VDRL (Confirmation with FTA-ABS if needed (Syphilis)).\nBe currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.\nPatients with EF<45% (heart failure patients).\nGFR < or equal to 35 (chronic kidney disease stage 3 or higher).\nLiver disease (elevated LFTs greater than 3x normal limit).\nAdvanced pulmonary disease (requiring home oxygen and/or less than 1 expected life span).\nProliferative diabetic retinopathy\nHemoglobin A1C greater than 7."
      ],
      "EnrollmentCount": [
            "14"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Group A (UCMSCs - 100 million)",
            "Pilot Phase: Group 1 (UCMSCs - 20 million)",
            "Pilot Phase: Group 3 (UCMSCs - 100 million)",
            "Group B (BMMSCs - 100 million)",
            "Pilot Phase: Group 2 (BMMSCs - 20 million)",
            "Pilot Phase: Group 4 (BMMSCs -100 million)",
            "Group C (Placebo)"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)",
            "Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)",
            "a single administration of placebo delivered via peripheral intravenous infusion."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "UCMSCs",
            "BMMSCs",
            "Placebo"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "July 1, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "June 28, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Joshua M Hare"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Miami"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States"
      ],
      "LocationFacility": [
            "ISCI / University of Miami Miller School of Medicine"
      ],
      "LocationState": [
            "Florida"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "33136"
      ],
      "MaximumAge": [
            "95 Years"
      ],
      "MinimumAge": [
            "21 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome."
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "University of Miami"
      ],
      "OrgStudyId": [
            "20170095"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "ISCI / University of Miami Miller School of Medicine"
      ],
      "OverallOfficialName": [
            "Joshua M Hare, MD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Terminated"
      ],
      "OversightHasDMC": [
            "No"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "March 23, 2020"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "Incidence (at one-month post infusion) of any treatment-emergent serious adverse events (TE-SAEs), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities, determined per the Investigator's judgment."
      ],
      "PrimaryOutcomeMeasure": [
            "Incidence of any treatment-emergent serious adverse events (TE-SAEs)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "one month post infusion"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "University of Miami"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Joshua M Hare"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Director of ISCI, Louis Lemberg Professor of Medicine"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "Change between baseline to follow up for the following panel of inflammatory markers: Interleukin-1 (IL-1), Interleukin-6 (IL-6), Tumor Necrosis Factor alpha (TNF\u03b1), and Vascular Endothelial Growth Factor (VEGF), & Stromal Cell Derived Factor (SDF-1a) levels from serum/plasma samples measured in pg/mL.",
            "Change between baseline to follow up for the following inflammatory marker: Serum High sensitivity C-Reactive Protein (hsCRP) in mg/L.",
            "Change in SCF levels from serum/plasma samples",
            "Change in endothelial function will be reported as the change in Endothelial Progenitor Cell Colony Forming Unit (EPC-CFU) assessed via blood sample assay",
            "FMD% will be assessed using brachial artery ultrasound"
      ],
      "SecondaryOutcomeMeasure": [
            "Change in inflammatory markers",
            "Change in hsCRP levels",
            "Change in Stem Cell Factor (SCF) levels",
            "Change in Endothelial Progenitor Cell-Colony Forming Units (EPC-CFUs)",
            "Change in Flow Mediated Diameter Percentage (FMD%)"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Baseline to week 2, baseline to month 1, baseline to month 3, baseline to month 6",
            "Baseline to week 2, baseline to month 1, baseline to month 3, baseline to month 6",
            "Baseline to week 2, baseline to month 1, baseline to month 3, baseline to month 6",
            "Baseline, 3 months",
            "Baseline, 3 months"
      ],
      "SeeAlsoLinkLabel": [
            "Interdisciplinary Stem Cell Institute at the University of Miami Miller School website"
      ],
      "SeeAlsoLinkURL": [
            "http://isci.med.miami.edu"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "April 12, 2018"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "June 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "February 23, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "February 6, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "February 15, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [
            "September 28, 2022"
      ],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [
            "September 28, 2022"
      ],
      "TargetDuration": [],
      "UnpostedEventDate": [
            "September 28, 2022",
            "September 28, 2022"
      ],
      "UnpostedEventType": [
            "Release",
            "Unrelease"
      ],
      "UnpostedResponsibleParty": [
            "Joshua M Hare, Director of ISCI, Louis Lemberg Professor of Medicine, University of Miami"
      ],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": [
            "COVID-19 Pandemic and lack of funding"
      ]
}